Overview
On September 11 2026, Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organization (CDMO) and subsidiary of Piramal Pharma Ltd (PPL), released a new microbiology laboratory for routine GMP use at its sterile injectable facility in Lexington, Kentucky. The laboratory is a key component of an $85 million Lexington expansion that aims to bring commercial‑scale fill/finish capability online by late 2027.
Facility Enhancements
The new laboratory more than triples the site’s existing microbiology testing space and consolidates all incubators within the new area. It is equipped with three new biosafety cabinets, enabling concurrent testing and reducing sample queue times. A dedicated sterility testing suite has been built with a Grade C background environment and houses a fully integrated Grade A sterility testing isolator. The isolator doubles the site’s sterility testing capacity, supports both open and closed filtration methods, and allows multiple samples to be processed simultaneously. Built‑in pass‑throughs permit direct movement of samples from the manufacturing floor to the lab, minimizing contamination risk and protecting product integrity.
Operational Impact
The upgraded suite is expected to reduce testing times by up to 50%, thereby accelerating batch releases, minimizing bottlenecks, and smoothing transitions as programs move from clinical to commercial stages. The added capacity also reduces supply risk and prepares the site for commercial‑scale demand across small‑molecule, bioconjugate, and peptide modality clients worldwide.
Leadership Quote
"The new microbiology laboratory represents an important milestone in our Lexington expansion journey," said Nathan Richardson, VP and Site Head, Piramal Pharma Solutions Lexington. "By enhancing sterility testing and microbiological quality capabilities, we are further strengthening our ability to support clients with high quality, reliable, and responsive services throughout the product life cycle. This investment reflects our continued commitment to operational excellence, patient safety, and the future growth of sterile injectable manufacturing in Lexington."
Expansion Timeline
While the microbiology laboratory and its sterility testing suite are now operational, the remainder of the Lexington expansion—including commercial‑scale fill/finish lines—is expected to become fully operational in late 2027.
About PPS and PPL
Piramal Pharma Solutions offers end‑to‑end development and manufacturing services across the drug life cycle through a globally integrated network of facilities in North America, Europe, and Asia. Services include drug discovery, process development, clinical trial supplies, commercial API supply, and finished dosage forms, as well as specialized capabilities such as highly potent APIs, antibody‑drug conjugates, sterile fill/finish, peptide products, and biologics manufacturing via its subsidiary Yapan Bio Private Limited. Piramal Pharma Ltd, the parent company, operates 17 global development and manufacturing facilities and a distribution network in over 100 countries, encompassing PPS, Piramal Critical Care, and Piramal Consumer Healthcare.